Barrington analyst Michael Petusky has maintained their bullish stance on MMSI stock, giving a Buy rating on September 11.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Michael Petusky has given his Buy rating due to a combination of factors that highlight Merit Medical Systems’ potential for growth and innovation. One key aspect is the company’s Wrapsody device, which has shown promising trial results, demonstrating a significant improvement in target lesion primary patency compared to the PTA cohort. The company is optimistic about obtaining a TPT add-on payment from CMS, which would enhance reimbursement and potentially boost future revenues.
Additionally, Merit Medical’s openness to mergers and acquisitions, supported by a strong balance sheet and cash flows, suggests potential for further growth through strategic acquisitions. The company’s business in China remains robust despite some recent challenges, and the upcoming CEO transition is expected to be smooth, ensuring continuity in its strategic direction. These factors, combined with a maintained price target of $103, underpin Petusky’s positive outlook on the stock.
In another report released on September 11, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $102.00 price target.